ETS family of transcription factors and the vascular system

Vascular Complications in Human Disease: Mechanisms and Consequences

Volumn , Issue , 2008, Pages 213-228

  Yamasaki, Masaomi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892281460     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84628-919-4_17     Document Type: Chapter

References (122)

1. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995;11:73-91.
2. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275(5302):965-967.
3. Shi Q, Rafli S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998;92(2):362-367.
4. Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2 (+) AC133 (+) endothelial precursor cells. Circ Res 2001;88(2):167-174.
5. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85(3):221-228.
6. Tamaki T, Akatsuka A, Ando K, et al. Identification of myogenic-endothelial progenitor cells in the interstitial spaces of skeletal muscle. J Cell Biol 2002;157(4):571-577.
7. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997;277(5322):48-50.
8. Dvorak HF, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 1985;227(4690):1059-1061.
9. Albini A, Soldi R, Giunciuglio D, et al. The angiogenesis induced by HIV-1 tat protein is mediated by the flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996;2(12):1371-1375.
10. Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996;93(6):2576-2581.
11. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15(2):290-298.
12. Yamada Y, Nezu J, Shimane M, Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 1997;42(3):483-488.
13. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGFD) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95(2):548-553.
14. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to flt-1 but not to flk-1/KDR. J Biol Chem 1994;269(41):25646-25654.
15. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001;114(Pt 5):853-865.
16. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005;438(7070):937-945.
17. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7(5):359-371.
18. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in flk-1-deficient mice. Nature 1995;376(6535):62-66.
19. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380(6573):439-442.
20. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376(6535):66-70.
21. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M. Involvement of flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001;61(3):1207-1213.
22. Shibuya M. Vascular endothelial growth factor (VEGF)-Receptor2: Its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium. 2006;13(2):63-69.
23. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87(7):1161-1169.
24. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277(5322):55-60.
25. Valenzuela DM, Griffiths JA, Rojas J, et al. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 1999;96(5):1904-1909.
26. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87(7):1171-1180.
27. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation. Nature 1995;376(6535):70-74.
28. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 1998;273(29):18514-18521.
29. Kim I, Kim HG, Moon SO, et al. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ Res 2000;86(9):952-959.
30. Kontos CD, Stauffer TP, Yang WP, et al. Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and akt. Mol Cell Biol 1998;18(7):4131-4140.
31. Oike Y, Akao M, Kubota Y, Suda T. Angiopoietin-like proteins: Potential new targets for metabolic syndrome therapy. Trends Mol Med 2005;11(10):473-479.
32. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6(4):389-395.
33. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NFkappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 1998;141(4):1083-1093.
34. Mettouchi A, Klein S, Guo W, et al. Integrin-specific activation of rac controls progression through the G (1) phase of the cell cycle. Mol Cell. 2001;8(1):115-127.
35. Lee MJ, Thangada S, Paik JH, et al. Akt-mediated phosphorylation of the G proteincoupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell 2001;8(3):693-704.
36. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit alpha V beta 3 integrinmediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001;7(9):1041-1047.
37. Navarro P, Caveda L, Breviario F, Mandoteanu I, Lampugnani MG, Dejana E. Catenin-dependent and -independent functions of vascular endothelial cadherin. J Biol Chem. 1995;270(52):30965-30972.
38. Bach TL, Barsigian C, Chalupowicz DG, et al. VE-cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res 1998;238(2):324-334.
39. Vittet D, Buchou T, Schweitzer A, Dejana E, Huber P. Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies. Proc Natl Acad Sci USA 1997;94(12):6273-6278.
40. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438(7070):946-953.
41. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999;98(6):769-778.
42. Hong YK, Harvey N, Noh YH, et al. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn 2002;225(3):351-357.
43. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004;5(1):74-80.
44. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002;3(3):411-423.
45. Leprince D, Gegonne A, Coll J, et al. A putative second cell-derived oncogene of the avian leukaemia retrovirus E26. Nature 1983;306(5941):395-397.
46. Watson DK, McWilliams-Smith MJ, Nunn MF, Duesberg PH, O'Brien SJ, Papas TS. The ets sequence from the transforming gene of avian erythroblastosis virus, E26, has unique domains on human chromosomes 11 and 21: Both loci are transcriptionally active. Proc Natl Acad Sci USA 1985;82(21):7294-7298.
47. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005;41(16):2462-2478.
48. Donaldson LW, Petersen JM, Graves BJ, McIntosh LP. Secondary structure of the ETS domain places murine ets-1 in the superfamily of winged helix-turn-helix DNA-binding proteins. Biochemistry 1994;33(46):13509-13516.
49. Graves BJ, Petersen JM. Specificity within the ets family of transcription factors. Adv Cancer Res 1998;75:1-55.
50. Nye JA, Petersen JM, Gunther CV, Jonsen MD, Graves BJ. Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif. Genes Dev 1992;6(6):975-990.
51. Kim CA, Phillips ML, Kim W, et al. Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression. EMBO J 2001;20(15):4173-4182.
52. Iwasaka C, Tanaka K, Abe M, Sato Y. ETS-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 1996;169(3):522-531.
53. Tanaka K, Oda N, Iwasaka C, Abe M, Sato Y. Induction of ets-1 in endothelial cells during reendothelialization after denuding injury. J Cell Physiol 1998;176(2):235-244.
54. Bories JC, Willerford DM, Grevin D, et al. Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the ets-1 proto-oncogene. Nature. 1995;377(6550):635-638.
55. Muthusamy N, Barton K, Leiden JM. Defective activation and survival of T cells lacking the ets-1 transcription factor. Nature 1995;377(6550):639-642.
56. Nakano T, Abe M, Tanaka K, Shineha R, Satomi S, Sato Y. Angiogenesis inhibition by transdominant mutant ets-1. J Cell Physiol 2000;184(2):255-262.
57. Rao VN, Papas TS, Reddy ES. Erg, a human ets-related gene on chromosome 21: Alternative splicing, polyadenylation, and translation. Science 1987;237(4815):635-639.
58. Ben-David Y, Giddens EB, Bernstein A. Identification and mapping of a common proviral integration site fli-1 in erythroleukemia cells induced by friend murine leukemia virus. Proc Natl Acad Sci USA 1990;87(4):1332-1336.
59. Spyropoulos DD, Pharr PN, Lavenburg KR, et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol 2000;20(15):5643-5652.
60. Hart A, Melet F, Grossfeld P, et al. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 2000;13(2):167-177.
61. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t (5;12) chromosomal translocation. Cell 1994;77(2):307-316.
62. Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, Orkin SH. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the ets-related factor TEL. EMBO J 1997;16(14):4374-4383.
63. Lopez RG, Carron C, Oury C, Gardellin P, Bernard O, Ghysdael J. TEL is a sequencespecific transcriptional repressor. J Biol Chem 1999;274(42):30132- 30138.
64. Oettgen P, Akbarali Y, Boltax J, Best J, Kunsch C, Libermann TA. Characterization of NERF, a novel transcription factor related to the ets factor ELF-1. Mol Cell Biol 1996;16(9):5091-5106.
65. Dube A, Akbarali Y, Sato TN, Libermann TA, Oettgen P. Role of the ets transcription factors in the regulation of the vascular-specific Tie2 gene. Circ Res 1999;84(10):1177-1185.
66. Iljin K, Dube A, Kontusaari S, et al. Role of ets factors in the activity and endothelial cell specificity of the mouse tie gene promoter. FASEB J 1999;13(2):377-386.
67. Chen Z, Fisher RJ, Riggs CW, Rhim JS, Lautenberger JA. Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETS1 antisense oligonucleotides. Cancer Res 1997;57(10):2013-2019.
68. Edel MJ. The ETS-related factor TEL is regulated by angiogenic growth factor VEGF in HUVE-cells. Anticancer Res 1998;18(6 A):4505-4509.
69. Tomita N, Morishita R, Taniyama Y, et al. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003;107(10):1411-1417.
70. Tanaka K, Abe M, Sato Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn J Cancer Res 1999;90(6):647-654.
71. Hashiya N, Jo N, Aoki M, et al. In vivo evidence of angiogenesis induced by transcription factor ets-1: ETS-1 is located upstream of angiogenesis cascade. Circulation 2004;109(24):3035-3041.
72. Wakiya K, Begue A, Stehelin D, Shibuya M. A cAMP response element and an ets motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene. J Biol Chem 1996;271(48):30823-30828.
73. Valter MM, Hugel A, Huang HJ, et al. Expression of the ets-1 transcription factor in human astrocytomas is associated with fms-like tyrosine kinase-1 (flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res 1999;59(21):5608-5614.
74. Kappel A, Schlaeger TM, Flamme I, Orkin SH, Risau W, Breier G. Role of SCL/Tal-1, GATA, and ets transcription factor binding sites for the regulation of flk-1 expression during murine vascular development. Blood 2000;96(9):3078-3085.
75. Elvert G, Kappel A, Heidenreich R, et al. Cooperative interaction of hypoxiainducible factor-2alpha (HIF-2alpha) and ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (flk-1). J Biol Chem 2003;278(9):7520-7530.
76. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92(6):735-745.
77. Teruyama K, Abe M, Nakano T, Takahashi S, Yamada S, Sato Y. Neurophilin-1 is a downstream target of transcription factor ets-1 in human umbilical vein endothelial cells. FEBS Lett 2001;504(1-2):1-4.
78. Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K, Sato Y. Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 2001;289(1):39-43.
79. Watanabe D, Takagi H, Suzuma K, et al. Transcription factor ets-1 mediates ischemiaand vascular endothelial growth factor-dependent retinal neovascularization. Am J Pathol. 2004;164(5):1827-1835.
80. Oda N, Abe M, Sato Y. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J Cell Physiol 1999;178(2):121-132.
81. Lelievre E, Mattot V, Huber P, Vandenbunder B, Soncin F. ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin. Oncogene 2000;19(20):2438-2446.
82. McLaughlin F, Hayes BP, Horgan CM, Beesley JE, Campbell CJ, Randi AM. Tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta down-regulate intercellular adhesion molecule (ICAM)-2 expression on the endothelium. Cell Adhes Commun 1998;6(5):381-400.
83. McLaughlin F, Ludbrook VJ, Kola I, Campbell CJ, Randi AM. Characterisation of the tumour necrosis factor (TNF) - (alpha) response elements in the human ICAM-2 promoter. J Cell Sci 1999;112(Pt 24) (Pt 24):4695-4703.
84. Hegen A, Koidl S, Weindel K, Marme D, Augustin HG, Fiedler U. Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler Thromb Vasc Biol 2004;24(10):1803- 1809.
85. Gaspar J, Thai S, Voland C, et al. Opposing functions of the ets factors NERF and ELF-1 during chicken blood vessel development. Arterioscler Thromb Vasc Biol 2002;22(7):1106-1112.
86. Christensen RA, Fujikawa K, Madore R, Oettgen P, Varticovski L. NERF2, a member of the ets family of transcription factors, is increased in response to hypoxia and angiopoietin-1: A potential mechanism for Tie2 regulation during hypoxia. J Cell Biochem 2002;85(3):505-515.
87. Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci USA 1998;95(7):3890-3895.
88. Zhu H, Traver D, Davidson AJ, et al. Regulation of the lmo2 promoter during hematopoietic and vascular development in zebrafish. Dev Biol. 2005;281(2):256-269.
89. Landry JR, Kinston S, Knezevic K, Donaldson IJ, Green AR, Gottgens B. Fli1, Elf1, and ETS1 regulate the proximal promoter of the LMO2 gene in endothelial cells. Blood 2005;106(8):2680-2687.
90. Lin Q, Lu J, Yanagisawa H, et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 1998;125(22):4565-4574.
91. DeVal S, Anderson JP, Heidt AB, Khiem D, Xu SM, Black BL. Mef2c is activated directly by ets transcription factors through an evolutionarily conserved endothelial cell-specific enhancer. Dev Biol 2004;275(2):424-434.
92. Lincoln DW, 2nd, Phillips PG, Bove K. Estrogen-induced ets-1 promotes capillary formation in an in vitro tumor angiogenesis model. Breast Cancer Res Treat 2003;78(2):167-178.
93. Wernert N, Okuducu AF, Pepper MS. ETS 1 is expressed in capillary blood vessels but not in lymphatics. J Pathol 2003;200(5):561-567.
94. Hultgardh-Nilsson A, Cercek B, Wang JW, et al. Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro. Circ Res 1996;78(4):589-595.
95. Zhan Y, Brown C, Maynard E, et al. ETS-1 is a critical regulator of ang II-mediated vascular inflammation and remodeling. J Clin Invest 2005;115(9):2508-2516.
96. Naito S, Shimizu S, Maeda S, Wang J, Paul R, Fagin JA. ETS-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells. Am J Physiol 1998;274(2 Pt 1):C472-480.
97. Zhang C, Kavurma MM, Lai A, Khachigian LM. ETS-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21WAF1/Cip1: ETS-1 regulates basal and and inducible p21WAF1/Cip: ETS-1 regulates basal and inducible p21WAF1/Cip1 transcription via distinct cis-acting elements in the p21WAF/Cip1 promoter. J Biol Chem 2003;278(30):27903-27909.
98. Goetze S, Kintscher U, Kaneshiro K, et al. TNFalpha induces expression of transcription factors c-fos, egr-1, and ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2. Atherosclerosis. 2001;159(1):93-101.
99. Bonello MR, Bobryshev YV, Khachigian LM. Peroxide-inducible ets-1 mediates platelet-derived growth factor receptor-alpha gene transcription in vascular smooth muscle cells. Am J Pathol 2005;167(4):1149-1159.
100. Santiago FS, Khachigian LM. ETS-1 stimulates platelet-derived growth factor Achain gene transcription and vascular smooth muscle cell growth via cooperative interactions with Sp1. Circ Res 2004;95(5):479-487.
101. Dandre F, Owens GK. Platelet-derived growth factor-BB and ets-1 transcription factor negatively regulate transcription of multiple smooth muscle cell differentiation marker genes. Am J Physiol Heart Circ Physiol 2004;286(6):H2042-51.
102. Liu MY, Eyries M, Zhang C, Santiago FS, Khachigian LM. Inducible platelet-derived growth factor D-chain expression by angiotensin II and hydrogen peroxide involves transcriptional regulation by ets-1 and Sp1. Blood 2006;107(6):2322-2329.
103. Iwasaka-Yagi C, Abe M, Sato Y. TGF-beta attenuates the transactivation activity of ets-1 despite its induction via the inhibition of DNA binding. Tohoku J Exp Med 2001;193(4):311-318.
104. Liu M, Leibowitz JL, Clark DA, et al. Gene transcription of fgl2 in endothelial cells is controlled by ets-1 and oct-1 and requires the presence of both Sp1 and Sp3. Eur J Biochem 2003;270(10):2274-2286.
105. Jahroudi N, Lynch DC. Endothelial-cell-specific regulation of von willebrand factor gene expression. Mol Cell Biol 1994;14(2):999-1008.
106. Sadler JE. Von willebrand factor. J Biol Chem 1991;266(34):22777-22780.
107. Schwachtgen JL, Janel N, Barek L, et al. ETS transcription factors bind and transactivate the core promoter of the von willebrand factor gene. Oncogene 1997;15(25):3091-3102.
108. Span PN, Manders P, Heuvel JJ, et al. Expression of the transcription factor ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002;21(55):8506-8509.
109. Mukherjee T, Kumar A, Mathur M, Chattopadhyay TK, Ralhan R. ETS-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2003;129(7):430-436.
110. Keehn CA, Smoller BR, Morgan MB. ETS-1 immunohistochemical expression in non-melanoma skin carcinoma. J Cutan Pathol 2004;31(1):8-13.
111. Keehn CA, Smoller BR, Morgan MB. Expression of the ets-1 proto-oncogene in melanocytic lesions. Mod Pathol 2003;16(8):772-777.
112. Mikami S, Oya M, Mizuno R, Murai M, Mukai M, Okada Y. Expression of ets-1 in human clear cell renal cell carcinomas: Implications for angiogenesis. Cancer Sci 2006;97(9):875-882.
113. Fujimoto J, Aoki I, Toyoki H, et al. Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology 2004;66(5):420-428.
114. Konno S, Iizuka M, Yukawa M, et al. Altered expression of angiogenic factors in the VEGF-ets-1 cascades in inflammatory bowel disease. J Gastroenterol 2004;39(10):931-939.
115. Redlich K, Kiener HP, Schett G, et al. Overexpression of transcription factor ets-1 in rheumatoid arthritis synovial membrane: Regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha. Arthritis Rheum 2001;44(2):266-274.
116. Kubo M, Czuwara-Ladykowska J, Moussa O, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003;163(2):571-581.
117. Fujimoto J, Aoki I, Toyoki H, Khatun S, Sato E, Tamaya T. Expression of ETS-1 related to angiogenesis in uterine endometrium during the menstrual cycle. J Biomed Sci 2003;10(3):320-327.
118. Fujimoto J, Toyoki H, Jahan I, et al. Sex steroid-dependent angiogenesis in uterine endometrial cancers. J Steroid Biochem Mol Biol 2005;93(2-5):161-165.
119. Sakaguchi H, Fujimoto J, Aoki I, Toyoki H, Sato E, Tamaya T. Expression of E26 transformation specific (ETS-1) related to angiogenesis in ovarian endometriosis. Fertil Steril 2004;82(2):507-510.
120. Nakerakanti SS, Kapanadze B, Yamasaki M, Markiewicz M, Trojanowska M. Fli1 and ETS1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006;281(35):25259-25269.
121. Lelievre E, Lionneton F, Mattot V, Spruyt N, Soncin F. ETS-1 regulates fli-1 expression in endothelial cells. identification of ETS binding sites in the fli-1 gene promoter. J Biol Chem 2002;277(28):25143-25151.
122. Hsu T, Trojanowska M, Watson DK. ETS proteins in biological control and cancer. J Cell Biochem 2004;91(5):896-903.